Volume 13, Issue 4 (Nov 2025)
Res Mol Med (RMM) 2025, 13(4): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khudhair Hassoon N, Rabbani Khorasgani M, F. Rostum I, Beikzadeh B. Protective Effects of Laser-Irradiated Streptococcus pneumoniae: A Novel Vaccine Candidate. Res Mol Med (RMM) 2025; 13 (4)
URL: http://rmm.mazums.ac.ir/article-1-631-en.html
URL: http://rmm.mazums.ac.ir/article-1-631-en.html
1- Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.
2- Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. ,m.rabbani@biol.ui.ac.ir
3- College of Cosmetic & Laser Techniques, Cordoba Private University, Al- Najaf Al- Ashraf - Iraq.
2- Department of Cell and Molecular Biology & Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. ,
3- College of Cosmetic & Laser Techniques, Cordoba Private University, Al- Najaf Al- Ashraf - Iraq.
Abstract: (26 Views)
Streptococcus pneumoniae (S. pneumoniae) is a significant cause of community-acquired pneumonia worldwide. Pneumococcal vaccines can prevent severe disease; however, their high cost, limited serotype coverage, and variable effectiveness across populations underscore the need for alternative vaccine strategies. Laser irradiation has been proposed as a novel approach to attenuate bacterial virulence while preserving immunogenicity.
Clinical isolates of S. pneumoniae were irradiated using low‑energy laser irradiation at wavelengths of 660 nm, 820 nm, and 915 nm to prepare an inactivated bacterial vaccine. Sterility testing confirmed complete bacterial inactivation. BALB/c mice were immunized three times at two-week intervals and were then challenged with wild-type S. pneumoniae. A commercial pneumococcal vaccine served as a positive control. Antibody responses (immunoglobulin M [IgM], IgG, and IgA) were measured, and survival was monitored for 21 days post-challenge.
Irradiation at 915 nm was the most effective for bacterial inactivation. Mice immunized with the 915 nm-inactivated vaccine showed significantly higher levels of IgM, IgG, and IgA compared to the unvaccinated group. Following bacterial challenge, all mice in this group survived, whereas 40% of mice immunized with the commercial vaccine died within 21 days after challenge.
Low-energy laser irradiation at 915 nm effectively inactivated S. pneumoniae while retaining its immunogenic properties. Immunization with this preparation elicited robust antibody responses and provided complete protection in mice, suggesting that it may serve as a novel pneumococcal vaccine candidate.
Clinical isolates of S. pneumoniae were irradiated using low‑energy laser irradiation at wavelengths of 660 nm, 820 nm, and 915 nm to prepare an inactivated bacterial vaccine. Sterility testing confirmed complete bacterial inactivation. BALB/c mice were immunized three times at two-week intervals and were then challenged with wild-type S. pneumoniae. A commercial pneumococcal vaccine served as a positive control. Antibody responses (immunoglobulin M [IgM], IgG, and IgA) were measured, and survival was monitored for 21 days post-challenge.
Irradiation at 915 nm was the most effective for bacterial inactivation. Mice immunized with the 915 nm-inactivated vaccine showed significantly higher levels of IgM, IgG, and IgA compared to the unvaccinated group. Following bacterial challenge, all mice in this group survived, whereas 40% of mice immunized with the commercial vaccine died within 21 days after challenge.
Low-energy laser irradiation at 915 nm effectively inactivated S. pneumoniae while retaining its immunogenic properties. Immunization with this preparation elicited robust antibody responses and provided complete protection in mice, suggesting that it may serve as a novel pneumococcal vaccine candidate.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
